N.P. Koper

1.4k citations

20 papers · 1.0k indexed · 1 hit paper · h-index 12

Impact in

Reproductive Medicine top 5%
- Ovarian function and disorders
Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology

Papers in ⓘ

Reproductive Medicine 9
- Ovarian cancer diagnosis and treatment 7
- Ovarian function and disorders 2
Obstetrics and Gynecology 3
- Endometrial and Cervical Cancer Treatments 3

Co-authors: Philippe Aftimos (5 shared papers)Lambertus A. Kiemeney (7 shared papers)Udai Banerji (3 shared papers)Ellen C.M. Mommers (3 shared papers)Elisabeth G.E. de Vries (2 shared papers)Ferry A.L.M. Eskens (2 shared papers)Carla M.L. van Herpen (2 shared papers)Cristina Saura (2 shared papers)
Journals: European Journal of Cancer (2 papers)Annals of Oncology (2 papers)Human Reproduction (2 papers)Clinical Chemistry and Laboratory Medicine (CCLM) (1 paper)Gynecologic Oncology (1 paper)
Partner nations: Netherlands United States United Kingdom

In The Last Decade

N.P. Koper

20 papers receiving 997 citations

Hit Papers

align trajectories log scale

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study 2019 · 400 citations

Peers

Countries citing papers authored by N.P. Koper

Since Specialization

Citations

This map shows the geographic impact of N.P. Koper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N.P. Koper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N.P. Koper more than expected).

Fields of papers citing papers by N.P. Koper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N.P. Koper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N.P. Koper. The network helps show where N.P. Koper may publish in the future.

Co-authors

The 25 scholars most cited alongside N.P. Koper, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with N.P. Koper Line = papers co-authored together N.P. Koper links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study The Lancet Oncology ·Udai Banerji, Carla M.L. van Herpen, Cristina Saura, Fiona Thistlethwaite, Simon Lord, Víctor Moreno, Iain R. Macpherson, Valentina Boni, Christian Rolfo, Elisabeth G.E. de Vries, Sylvie Rottey, Jill J.J. Geenen, Ferry A.L.M. Eskens, Marta Gil-Martín, Ellen C.M. Mommers, N.P. Koper, Philippe Aftimos Hit paper breakdown →	2019	400
2	A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol Human Reproduction ·Paul Devroey, R. Boostanfar, N.P. Koper, Bernadette Mannaerts, Pieta C. IJzerman‐Boon, Bart C.J.M. Fauser, (unknown)	2009	161
3	LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer Annals of Oncology ·C. Saura Manich, Joyce O’Shaughnessy, Philippe Aftimos, Evelyn van den Tweel, M. Oesterholt, Santiago Escrivá-de-Romaní, N. Quenel Tueux, T.J.Y. Tan, Joline S.J. Lim, Sylvain Ladoire, Anne Armstrong, Tim Crook, Agostina Stradella, Giulia Bianchi, Renée L. Mulder, N.P. Koper, Nicholas C. Turner	2021	85
4	Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis British Journal of Urology ·Lambertus A. Kiemeney, J. Alfred Witjes, R.P. Heijbroek, N.P. Koper, André L. M. Verbeek, F.M.J. Debruyne, (unknown)	1994	76
5	Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis JAMA Neurology ·Jeffrey A. Cohen, Anna N. Belova, Krzysztof Selmaj, Christian Wolf, Maria Pia Sormani, Janine Oberyé, Evelyn van den Tweel, R. J. Mulder, N.P. Koper, Gerrit Voortman, Frederik Barkhof	2015	59
6	A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer. Journal of Clinical Oncology ·Cristina Saura, Fiona Thistlethwaite, Udai Banerji, Simon Lord, Víctor Moreno, Iain R. Macpherson, Valentina Boni, Christian Rolfo, Elisabeth G.E. de Vries, Carla M.L. van Herpen, Sylvie Rottey, Jill J.J. Geenen, Ferry A.L.M. Eskens, Marta Gil-Martín, Ellen C.M. Mommers, N.P. Koper, R. J. Mulder, Philippe Aftimos	2018	53
7	Bladder cancer incidence and survival in the south-eastern part of the Netherlands, 1975–1989 European Journal of Cancer ·Lambertus A. Kiemeney, J.W.W. Coebergh, N.P. Koper, L.H. van der Heijden, R.P.E. Pauwels, R.F.M. Schapers, André L. M. Verbeek	1994	37
8	Improvement of Clinical Staging in Cervical Cancer with Serum Squamous Cell Carcinoma Antigen and CA 125 Determinations Gynecologic Oncology ·Leon F.A.G. Massuger, N.P. Koper, Chris M.G. Thomas, Koen E.L. Dom, Charles P.T. Schijf	1997	29
9	Serum CA 125 measurements to identify patients with endometrial cancer who require lymphadenectomy. PubMed ·N.P. Koper, Leon F.A.G. Massuger, Chris M.G. Thomas, Lambertus A. Kiemeney, André L. M. Verbeek	1998	27
10	Ovarian cancer incidence (1989–1991) and mortality (1954–1993) in the Netherlands Obstetrics and Gynecology ·N.P. Koper, Lambertus A. Kiemeney, Leon Massuger, Charles R. Thomas, C.P.T. Schijf, A VERBEEK	1996	24
11	Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results Multiple Sclerosis Journal ·Krzysztof Selmaj, Frederik Barkhof, Anna N Belova, Christian Wolf, Evelyn RW van den Tweel, Janine Oberyé, R. J. Mulder, David Egging, N.P. Koper, Jeffrey A. Cohen, (unknown)	2017	19
12	386MO Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial Annals of Oncology ·Philippe Aftimos, Nicholas C. Turner, Joyce O’Shaughnessy, Evelyn van den Tweel, M. Oesterholt, Santiago Escrivá-de-Romaní, N. Quenel Tueux, Tira J. Tan, Joline S.J. Lim, Sylvain Ladoire, A.C. Armstronh, Agostina Stradella, Giulia Bianchi, Marco Colleoni, Emilie Kaczmarek, Kevin Punie, X. Song, N.P. Koper, C. Saura Manich	2023	16
13	333 Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985 European Journal of Cancer ·Carla M. van Herpen, Udai Banerji, Ellen C.M. Mommers, N.P. Koper, Peter Goedings, Juanita Lopez, Ahmad Awada, Helle‐Brit Fiebrich, Philippe Aftimos	2015	10
14	Quantitation of IgG and IgM Human Anti-Mouse Antibodies (HAMA) Interference in CA 125 Measurements Using Affinity Chromatography Clinical Chemistry and Laboratory Medicine (CCLM) ·N.P. Koper, Chris M.G. Thomas, Leon F.A.G. Massuger, Martin F.G. Segers, André J. Olthaar, André L. M. Verbeek	1998	7
15	Mutagen sensitivity in patients with familial and non-familial urothelial cell carcinoma International Journal of Cancer ·Katja K.H. Aben, Jacqueline Cloos, N.P. Koper, Boudewijn J.M. Braakhuis, J.A. Witjes, Lambertus A. Kiemeney	2000	7
16	An illustration of the clinical relevance of detecting human antimouse antibody interference by affinity chromatography European Journal of Obstetrics & Gynecology and Reproductive Biology ·N.P. Koper, Leon F.A.G. Massuger, Chris M.G. Thomas, C Beyer, Marinus J. Crooy	1999	5
17	Comparison of four 'second generation' immunoassay systems to determine CA 125 in serum by using a graphical approach to method comparison analysis. PubMed ·N.P. Koper, Chris M.G. Thomas, Leon F.A.G. Massuger, M F Segers, Lambertus A. Kiemeney, André L. M. Verbeek	1997	5
18	Serum CA 125 concentrations in women of different ages, hormonal statuses, orclinical conditions International Journal of Gynecological Cancer ·N.P. Koper, Chris M.G. Thomas, L.F.A.G. Massuger, Marius J. van der Mooren, Lambertus A. Kiemeney, A.L.M. Verbeek	1997	4
19	A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol Human Reproduction ·P. Devroey, R. Boostanfar, N.P. Koper, Bernadette Mannaerts, Paul E. Verweij, Barbara J. Stegmann, Pieta C. IJzerman‐Boon, B.C.J.M. Fauser, (unknown)	2014	4
20	Comparison of Copaxone^® and Synthon's therapeutically equivalent glatiramer acetate. PubMed ·Richard Arends, D Wang, M Buurman, J Luten, N.P. Koper, Christian Wolf, M Scheren	2019	1

About N.P. Koper

N.P. Koper is a scholar working on Reproductive Medicine, Obstetrics and Gynecology, Radiology, Nuclear Medicine and Imaging, Oncology and Genetics, having authored 20 papers that have together received 1.0k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (7 papers), HER2/EGFR in Cancer Research (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Cancer Treatment and Pharmacology (3 papers), Endometrial and Cervical Cancer Treatments (3 papers), Bladder and Urothelial Cancer Treatments (3 papers), Advanced Biosensing Techniques and Applications (3 papers) and Ovarian function and disorders (2 papers). The work is most often cited by research in Reproductive Medicine (231 citations), Oncology (583 citations), Radiology, Nuclear Medicine and Imaging (351 citations), Obstetrics and Gynecology (63 citations) and Cancer Research (115 citations). N.P. Koper has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Philippe Aftimos, Lambertus A. Kiemeney, Udai Banerji, Ellen C.M. Mommers, Elisabeth G.E. de Vries, Ferry A.L.M. Eskens, Carla M.L. van Herpen, Cristina Saura, Fiona Thistlethwaite and Víctor Moreno. Their work appears in journals such as European Journal of Cancer, Annals of Oncology, Human Reproduction, Clinical Chemistry and Laboratory Medicine (CCLM) and Gynecologic Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact